CytomX Therapeutics (NASDAQ:CTMX) CFO Christopher Ogden Sells 19,323 Shares

March 20, 2026 by InsiderTrades.com

Key Points

CEO Sean McCarthy sold 118,969 shares on March 17 at an average price of $6.42 for a total of $763,780.98, trimming his holding by 9.93% to 1,078,922 shares (≈$6.93M).
Disappointing quarterly results: CytomX reported EPS of -$0.22 versus a -$0.08 consensus and revenue of $0.66M versus $7.33M expected, contributing to near‑term negative pressure on the stock.
Despite earnings and insider sales, several analysts raised price targets (consensus rating "Moderate Buy," target $13.22) and the shares rallied ~8.3; the company also priced a roughly $234M equity offering, which strengthens the runway but is dilutive, creating mixed investor sentiment.

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CFO Christopher Ogden sold 19,323 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $124,053.66. Following the completion of the sale, the chief financial officer directly owned 296,948 shares in the company, valued at approximately $1,906,406.16. This represents a 6.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

CytomX Therapeutics Price Performance

Shares of NASDAQ:CTMX opened at $4.68 on Friday. The business has a fifty day moving average price of $5.28 and a 200-day moving average price of $4.10. The company has a market capitalization of $795.64 million, a PE ratio of -118.50 and a beta of 2.44. CytomX Therapeutics, Inc. has a 1-year low of $0.40 and a 1-year high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The firm had revenue of $0.66 million for the quarter, compared to analysts' expectations of $7.33 million. CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. On average, sell-side analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

Key Headlines Impacting CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

Positive Sentiment: Barclays raised its price target to $16 and moved CTMX to "overweight," giving investors a high‑profile bullish thesis that likely contributed to buying interest. Barclays price-target raise
Positive Sentiment: Guggenheim increased its forecast/price target (joined by other firms raising targets), reinforcing optimistic expectations for the pipeline and supporting the uptick. Guggenheim Forecasts Strong Price Appreciation for CytomX
Positive Sentiment: Wedbush (and other sell‑side shops) also lifted price targets in the same window, creating a cluster of upgrades that appear to be driving momentum. Wedbush Raises Price Target
Positive Sentiment: Trading volume spiked after the analyst upgrade cycle, indicating the upgrades translated into real buying rather than just headlines. Strong Trading Volume After Analyst Upgrade
Neutral Sentiment: CytomX priced an equity offering for roughly $234 million — this materially extends runway but will be dilutive, so its net impact is mixed for shareholders. Equity Offering Announcement
Negative Sentiment: CTMX recently missed quarterly estimates (EPS and revenue), a near‑term negative that adds volatility and raises questions about current execution vs. investor expectations. Shares Down on Disappointing Earnings
Negative Sentiment: An analyst trimmed the Q1 EPS forecast, increasing uncertainty around near‑term results and guidance. Q1 EPS Forecast Decreased
Negative Sentiment: Several insiders — including CEO Sean McCarthy (sold ~118,969 shares for ~$763,780) plus CFO and other senior execs — sold stock on March 17; while sales can be routine, clustered insider selling can sap sentiment. Insider Sales Report
Negative Sentiment: At least one sell‑side commentary cautioned that early clinical data may not fully justify elevated valuation, adding a note of skepticism for momentum traders. Seeking Alpha valuation caution

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC raised its holdings in CytomX Therapeutics by 4.5% during the fourth quarter. Squarepoint Ops LLC now owns 49,897 shares of the biotechnology company's stock valued at $213,000 after acquiring an additional 2,169 shares during the period. Wells Fargo & Company MN boosted its stake in shares of CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 3,000 shares during the period. Velan Capital Investment Management LP grew its position in shares of CytomX Therapeutics by 6.7% during the third quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biotechnology company's stock worth $255,000 after purchasing an additional 5,000 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in CytomX Therapeutics during the 3rd quarter valued at approximately $25,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in CytomX Therapeutics during the 4th quarter valued at approximately $35,000. Hedge funds and other institutional investors own 67.77% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the company. Jefferies Financial Group increased their target price on CytomX Therapeutics from $8.00 to $16.00 and gave the company a "buy" rating in a research note on Wednesday. Oppenheimer restated an "outperform" rating and issued a $12.00 target price on shares of CytomX Therapeutics in a report on Monday. Cantor Fitzgerald lifted their target price on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 4th. Piper Sandler increased their price target on CytomX Therapeutics from $6.50 to $10.00 and gave the company an "overweight" rating in a report on Tuesday, January 20th. Finally, JPMorgan Chase & Co. raised CytomX Therapeutics from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $7.00 to $12.00 in a report on Monday. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, CytomX Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $13.22.

Get Our Latest Stock Report on CytomX Therapeutics

About CytomX Therapeutics

(Get Free Report)

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX's pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.